Journals / BEYOGLU EYE JOURNAL / 2021 / Cilt: 6 - Sayı: 4

Is There a Relationship between Statin Use and Corneal Specular Microscopy and Topography Findings?

Pages
280–284
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Statins may have beneficial effects on cornea morphology.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Information about the possible effect of statins on the human corneal endothelium is still not clear.
📊
Key Findings & Data:Methods: Thirty-four patients using a statin (atorvastatin) as hyperlipidemia treatment (Group 1) and 34 age- and sexmatched healthy subjects (Group 2) were prospectively included in the study.
💡
Conclusion & Impact:Statins may have beneficial effects on cornea morphology.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: Information about the possible effect of statins on the human corneal endothelium is still not clear. This study was the first known investigation of the influence of statins on corneal specular microscopy (SM) and topography parameters. Methods: Thirty-four patients using a statin (atorvastatin) as hyperlipidemia treatment (Group 1) and 34 age- and sexmatched healthy subjects (Group 2) were prospectively included in the study. Demographic data and ophthalmic findings of participants were reported and analyzed. Cellular morphology was evaluated using the noncontact SM and corneal endothelial cell density (CECD) (cells/mm2), polymegathism (coefficient of variation in cell size [CV], %), and pleomorphism (% hexagonal cells [Hex]) data. Anterior chamber depth and volume, iridocorneal angle degree, average keratometry diopters were also measured with corneal topography. Results: The mean age was 53.03±7.23 years (range: 38–73 years) for Group 1 and 53.15±10.7 years (range: 34–80 years) for Group 2 (p=0.958). Group 1 consisted of 11 female and 23 male patients and Group 2 included 13 female and 21 male participants (p=0.798). The mean CECD density was significantly higher in Group 1 when compared with that of Group 2 (2544.34±244.76 cells/mm2 [range: 2126.60–3107.00 cells/mm2] vs 2404.53±285.46 cells/mm2 [range: 1839.80–2892.30 cells/mm2], p=0.034). There were no significant statistical differences in the CV and Hex values between the groups (p=0.450 and p=0.717, respectively). The corneal topographic measurements were also not significantly different. Conclusion: The findings of this study revealed higher CECD values in statin users. Statins may have beneficial effects on cornea morphology.

🔖

Cite This Article

KURTUL, B. E., KURTUL, A., ERGASHEV, K. (2021). Is There a Relationship between Statin Use and Corneal Specular Microscopy and Topography Findings?. BEYOGLU EYE JOURNAL, Cilt: 6 - Sayı: 4, 280–284. https://ajindex.com/articles/406551

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Arıcı C, Arslan OS, Dikkaya F. Corneal endothelial cell density and morphology in healthy Turkish eyes. J Ophthalmol 2014;2014:852624
  2. Taurone S, Miglietta S, Spoletini M, Feher J, Artico M, Papa V, et al. Age related changes seen in human cornea in formalin fixed sections and on biomicroscopy in living subjects: A comparison. Clin Anat 2020;33:245–56
  3. Golu A, Gheorghişor I, Bălăşoiu AT, Baltă F, Osiac E, Mogoantă L, et al. The effect of ultraviolet radiation on the cornea - experimental study. Rom J Morphol Embryol 2013;54:1115–20
  4. Mittanamalli S Sridhar. Anatomy of cornea and ocular surface. Indian J Ophthalmol 2018;66:190–4
  5. Edelhauser HF. The balance between corneal transparency and edema: the Proctor Lecture. Invest Ophthalmol Vis Sci 2006;47:1754–67
  6. Abdellah MM, Ammar HG, Anbar M, Mostafa EM, Farouk MM, Sayed K, et al. Corneal endothelial cell density and morphology in healthy egyptian eyes. J Ophthalmol 2019;2019:6370241
  7. Ooi KG, Khoo P, Vaclavik V, Watson SL. Statins in ophthalmology. Surv Ophthalmol 2019;64:401–32
  8. Morishita R, Tomita N, Ogihara T. HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque. Curr Drug Targets 2002;3:379–85
  9. Amarenco P, Benavente O, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. Stroke 2009;40:1405– 9
  10. Schmeer C, Kretz A, Isenmann S. Therapeutic potential of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the treatment of retinal and eye diseases. CNS Neurol Disord Drug Targets 2007;6:282–7
  11. Lee J, Lee SH, Hur KY, Woo SY, Kim SW, Kang WK. Statins and the risk of gastric cancer in diabetes patients. BMC Cancer 2012;12:596
  12. Crockett SD, Hansen RA, Stürmer T, Schectman R, Darter J, Sandler RS, et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis 2012;18:1048–56
  13. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015–21
  14. McGwin G Jr, Owsley C, Curcio CA, Crain RJ. The association between statin use and age related maculopathy. Br J Ophthalmol 2003;87:1121–5
  15. Ma L, Wang Y, Du